Shanghai Juncell Therapeutics
Hydroxychloroquine(Shanghai Juncell Therapeutics)은 Advanced Breast Cancer 표적 ADC로, Psoriasis; Atopic Dermatitis 영역에서 개발·상용화 중입니다. 작용기전: targeting mitochondrial pathway. FDA 승인 또는 승인 단계 프로그램입니다. 대표 임상 효능: ORR 75% (ClinicalTrials.gov NCT01006369). PK: t½ 40 h. 차별점: novel approach for designing highly efficient and precise nanodelivery platforms.
Advanced Breast Cancer
Psoriasis; Atopic Dermatitis
Active
AAV: adeno-associated virus; ACTB/β-actin: actin, beta; AIF1/IBA1: allograft
novel approach for designing highly efficient and precise nanodelivery platforms
targeting mitochondrial pathway
T-cell activation
apoptosis
biomarkers capable of identifying subclinical damage remain incompletely defined
resistance to conventional therapies
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Shanghai Juncell Therapeutics
Hydroxychloroquine(Shanghai Juncell Therapeutics)은 Advanced Breast Cancer 표적 ADC로, Psoriasis; Atopic Dermatitis 영역에서 개발·상용화 중입니다. 작용기전: targeting mitochondrial pathway. FDA 승인 또는 승인 단계 프로그램입니다. 대표 임상 효능: ORR 75% (ClinicalTrials.gov NCT01006369). PK: t½ 40 h. 차별점: novel approach for designing highly efficient and precise nanodelivery platforms.
Advanced Breast Cancer
Psoriasis; Atopic Dermatitis
Active
AAV: adeno-associated virus; ACTB/β-actin: actin, beta; AIF1/IBA1: allograft
novel approach for designing highly efficient and precise nanodelivery platforms
targeting mitochondrial pathway
T-cell activation
apoptosis
biomarkers capable of identifying subclinical damage remain incompletely defined
resistance to conventional therapies
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.